Skip to content
lifestyle.faithfamilyamerica.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
HUTCHMED (China) Limited
HUTCHMED Highlights Sovleplenib ESLIM-02 Phase III Data in Warm Antibody Autoimmune Hemolytic Anemia Presented at EHA 2026 Congress
June 11, 2026
HUTCHMED Announces NDA Acceptance in China with Priority Review Status and Breakthrough Designation for Sovleplenib for the Treatment of Warm Antibody Autoimmune Hemolytic Anemia
April 29, 2026
HUTCHMED Highlights Data to be Presented at AACR Annual Meeting 2026
April 8, 2026
HUTCHMED to Announce 2025 Final Results
February 11, 2026
←
Previous Page
1
2